Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|September 9, 2024
Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantationPaula Muñiz, María Martínez-García, Rebeca Bailén, et al.
JAMA Network Open|February 25, 2025
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin LymphomaLina Camacho-Arteaga, Gloria Iacoboni, Mi Kwon, et al.
Annals of Hematology|May 7, 2022
Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphismsMiren Vallejo, Paula Muñiz, Mi Kwon, et al.
Transplantation and Cellular Therapy|March 15, 2023
Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell LymphomaMariana Bastos-Oreiro, Laura Sanz-Villanueva, Paula Muñiz, et al.
British Journal of Haematology|December 13, 2024
Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapyIsmael de la Iglesia-San Sebastián, Miguel López-Esteban, Mariana Bastos-Oreiro, et al.
Transfusion|August 20, 2022
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapyPablo Silva de Tena, Rebeca Bailén, Gillen Oarbeascoa, et al.
AIDS (London, England)|April 2, 2019
Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disordersMi Kwon, Rebeca Bailén, Pascual Balsalobre, et al.
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Frontiers in Immunology|June 7, 2021
Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic TransplantRebeca Bailén, José Luis Vicario, Laura Solán, et al.
Pageof 5